NCT07241247CompletedPhase 4
Evaluation the of Role of Vitamin D Supplement on Tumor Response, Inflammation and Apoptosis in Patients With Stage II or III Colorectal Cancer Receiving Chemotherapy.
Clinical Study Evaluating the Role of Vitamin D Supplement in Patients With Colorectal Cancer Receiving Chemotherapy
Source: ClinicalTrials.gov · Last updated 21 Nov 2025
Brief summary (registry, in English)
The aim of this work is to assess the of role of Vitamin D supplement on tumor response, inflammation and apoptosis in patients with stage II or III colorectal cancer receiving chemotherapy using BAX protein and Tumor necrosis factor - alpha (TNF- α) both are measured at baseline and after 6 months.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 44 (actual)
- First submitted
- 13 Nov 2025
- Start date
- 31 Jul 2024
- Primary completion date
- 10 Jun 2025
- Lead sponsor
- Tanta University
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT07241247
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 44
- From 31 Jul 2024 to the primary completion date, 10 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are taking vitamin D-containing supplements (\>800 IU/day) unless they discontinued vitamin D supplementation at least 2 months prior to enrollment.
Other illness
- Patients with metastatic colorectal cancer (CRC).
- Patients with parathyroid disorders.
- Patients had a history of hypercalcemia.
Who the study is looking for
- Patients with histologically and radiologically confirmed diagnosis of stage II or III colorectal cancer.
- Performance status 0-1 according to the Eastern Cooperative Oncology Group (ECOG).
- Patients who received FOLFOX or XELOX as first line chemotherapy.
- Both genders.
- Age ≥18.
- Patients with adequate hematologic parameters (white blood cell count ≥3000/mm3, granulocytes ≥1500/mm3, platelets ≥100,000/mm3, hemoglobin ≥ 8 gm/l).
- Patients with normal renal functions.
- Patients with normal hepatic functions.
- Patients with sufficient 25(OH) Vitamin D level (30-100 ng/mL).
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Menofia university Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.